BCL11A is a developmental stage-specific repressor of γ-globin expression, and its erythroid-specific enhancer has been a productive therapeutic target^[3]. Exagamglogene autotemcel (exa-cel), which disrupts the +58 erythroid enhancer of BCL11A, has produced high rates of transfusion independence and has received regulatory approval for transfusion-dependent β-thalassemia and sickle cell disease^[4,5]. Preclinical studies suggest that even erythroid-restricted enhancer disruption of BCL11A could subtly affect erythroid proliferation or differentiation^[6-8], justifying continued surveillance.

Direct editing of the HBG1 and HBG2 promoters offers a more physiological alternative. Naturally occurring HPFH mutations have shown for decades that disruption of transcription-factor binding motifs within the γ-globin promoters can sustain high HbF levels without apparent adverse hematological consequences^[9,10]. Promoter editing directly recreates protective HPFH variants, minimizing interference with broader transcriptional networks^[11,12]. In the EdiThal study, Cas12a editing generated the desired insertion-deletion patterns efficiently, but the report did not include a dedicated off-target analysis and follow-up remains short^[1]. Whether promoter editing ultimately provides a biological advantage over enhancer-directed approaches will depend on long-term confirmation of preserved erythropoiesis and durable stem-cell function.

First-generation CRISPR-Cas9 editing enabled efficient double-strand DNA cleavage^[5,13]. However, double-strand breaks activate DNA-damage responses and may generate heterogeneous repair outcomes, chromosomal rearrangements, and p53 activation^[14-16]. Cas12a offers a distinct PAM requirement, staggered DNA cleavage, simplified multiplex editing through a single CRISPR RNA, and high specificity in some contexts^[17-19]. The indel spectrum generated by Cas12a at the HBG promoters closely resembles naturally occurring HPFH mutations^[1,12], and engineered Cas12a variants may further improve flexibility^[18].

Base-editing technologies permit single-nucleotide conversion without double-strand breaks, reducing genomic instability while precisely recreating protective variants^[20,21]. HBG promoter base editing has entered early clinical evaluation^[22,23]. Prime editing enables versatile sequence replacement without donor DNA or double-strand breaks, although efficiency in hematopoietic stem cells remains limiting^[24]. In parallel, CRISPR interference, CRISPR activation, and epigenome editing seek to modulate gene expression without permanently altering genomic sequences, potentially providing reversible options^[25,26]. As is summarized in Table 1, BCL11A enhancer editing and HBG promoter editing represent two distinct strategies for HbF induction, differing in their underlying mechanisms, biological rationale, off-target risks, safety profiles, and clinical evidence.

Several mechanistic features make Cas12a well suited to HBG promoter editing. First, the TTTV PAM preferred by wild-type AsCas12a is abundant in the AT-rich γ-globin promoter region, expanding targetable sites compared with the NGG PAM required by commonly used SpCas9 variants^[17,18]. Second, Cas12a produces staggered 5'-overhangs that yield a narrower, more predictable indel spectrum matching naturally occurring HPFH deletions^[1,12]. Third, Cas12a processes its own CRISPR RNA from a single polycistronic transcript, simplifying multiplex editing of HBG1 and HBG2^[17]. Fourth, because AsCas12a is derived from Acidaminococcus spp., preexisting adaptive immunity may be less prevalent than against Staphylococcus aureus or Streptococcus pyogenes Cas9 proteins^[27]. These features may make Cas12a particularly suitable for T-rich targets, multiplex editing, and potentially in vivo applications, although Cas9 may remain preferable in other settings.

Any double-strand-break-mediated editing strategy must be evaluated for genomic consequences. CRISPR-Cas9 editing can induce large deletions, complex rearrangements, and chromothripsis at on-target sites^[14-16], and similar risks apply to Cas12a. Unbiased methods such as GUIDE-seq, targeted translocation assays (for example, CAST-Seq), and long-read sequencing are needed to detect both small off-target indels and large structural variants^[28-30]. Because HBG1 and HBG2 are paralogous sequences separated by only about 5 kb, simultaneous editing can generate a recurrent intergenic deletion whose clonal consequences require monitoring^[1,12].

Preexisting or induced immunity to Cas proteins is another translational consideration^[27]. Myeloablative busulfan conditioning also contributes to long-term risks, including clonal expansion and secondary malignancies; a case of acute myeloid leukemia after lentiviral gene therapy underscores the importance of lifelong surveillance^[31]. Non-genotoxic conditioning regimens, such as CD117-targeted antibody-drug conjugates, could reduce this burden^[32]. Finally, manufacturing complexity, cost, and the need for specialized transplantation centers limit equitable access.

The next phase of β-hemoglobinopathy gene therapy will be shaped by greater precision in the edit, less invasive delivery and conditioning, and better characterization of edited cell products. Base and prime editing will continue to refine the installation of protective single-nucleotide variants without double-strand breaks^[20-24], and epigenome editing may offer a reversible route to HbF induction^[25,26]. In vivo hematopoietic stem-cell editing, exemplified by CD117-targeted lipid nanoparticles delivering mRNA-encoded editors, could eliminate ex vivo manipulation^[33], and patient-specific in vivo editing has shown proof-of-concept in other genetic diseases^[34].

Machine-learning models are increasingly used to predict guide activity and off-target potential across Cas systems^[19]. Single-cell sequencing and long-read sequencing are moving from research tools toward quality-control assays that resolve clonal composition and structural variation^[29,30]. Beyond therapeutics, CRISPR-based diagnostics, including Cas13a assays for nucleic acid detection in accessible samples, illustrate the expanding scope of CRISPR technologies in hematology and oncology^[35,36], and gene editing is being integrated into cancer treatment strategies^[37].

Taken together, these developments suggest that β-thalassemia gene therapy is entering an era of increasing precision rather than simply increasing editing efficiency. The field has progressed from lentiviral gene addition to enhancer editing, promoter editing, base editing, and potentially prime editing, with each generation aiming to maximize efficacy while minimizing unintended consequences^{[20-24,38-40]}. Within this continuum, HBG promoter editing is promising because it emulates a naturally benign genetic condition. Nevertheless, the present study is limited by its small sample size, short follow-up, and early termination. Future head-to-head comparisons of the two editing strategies, together with long-term analyses of clonal stability, erythropoiesis, off-target effects, and stem-cell durability, will determine the optimal approach for HbF induction. The current data provide proof-of-concept that precise editing of the γ-globin promoters may represent a promising therapeutic approach for β-thalassemia and other β-hemoglobinopathies. Taken together, these developments suggest that β-thalassemia gene therapy is entering an era of increasing precision rather than simply increasing editing efficiency. The field now encompasses lentiviral gene addition^[38-40] alongside Cas9 enhancer editing^[4,5], Cas12a promoter editing^[1,2], base editing^[20-23], and prime editing^[24]; these strategies represent parallel and complementary approaches rather than sequential replacements, each aiming to maximize efficacy while minimizing unintended biological consequences. HBG promoter editing is particularly promising because it directly emulates a naturally benign genetic condition^[9,11,12]. Nevertheless, the current evidence remains limited by small sample sizes, short follow-up, and early trial termination^[1]. Future head-to-head comparisons of enhancer and promoter editing, together with long-term analyses of clonal stability, erythropoiesis, off-target effects, and stem-cell durability, will determine the optimal approach for HbF induction. The available data provide proof-of-concept that precise editing of the γ-globin promoters may represent a promising therapeutic strategy for β-thalassemia and other β-hemoglobinopathies^[1].